Pod Insights Pharmacy Podcast Network Asembia's Specialty Pharmacy Summit 2026 Rewind | Part 2/6 About this episode This is the Pharmacy Podcast Network's ASEMBIA 2026 rewind! We're dedicated to bringing you inside coverage of the pharmacy nation's biggest events with on the street style interviews with keynote speakers, attendees, exhibitors, and recurring guests who make each year special.
This is part two of our six part series!
We'd like to thank Nested Knowledge for sponsoring this episode!
On this episode we interview:
Keith Kallmes - Nested Knowledge
Hannah Baxter and Andrew Rouff, MMIT - The Dedham Group
Heather Bonome - URAC
Jeremy Richardson - Gifthealth
Joe DePinto - McKesson
Johny Kello - MatchRx
Shawn Griffin - URAC
Transcript 0:03 Speaker 00 Are systematic reviews taking months? There's a better way. Nested Knowledge is an AI-powered evidence synthesis platform built specifically for life sciences teams working under tight timelines. From literature search to metadata analysis, everything happens in one place. Smart Screener evaluates thousands of studies against your criteria in minutes. Smart MA extraction pulls quantitative data from tables and builds your analysis automatically. Smart Critical Appraisal assesses bias using established frameworks like JBI and SIGN with full transparency into every decision. The result? Publication-ready PRISMA diagrams, forest plots, and critical appraisal visuals, all
0:47 Speaker 00 traceable, all auditable, and all generated from a single platform. Whether you're in medical or regulatory affairs, health economics, and outcomes research, Nested Knowledge helps you produce rigorous evidence synthesis in days, not months. Ready to see how it works? Visit nested-knowledge.com to schedule a demo. Nested Knowledge: The standard in evidence synthesis.
1:21 Speaker 01 You are listening to the global network of podcasters dedicated to the pharmacy profession. Welcome to the Pharmacy Podcast Network.
1:41 Speaker 00 Each year, ASEMBIAS Specialty Pharmacy Summit is at the epicenter of the pharmacy industry, providing a unique opportunity for stakeholders throughout the industry to understand challenges, generate solutions, and define the future. This is the Pharmacy Podcast Network's ASEMBIAS 2026 Rewind.
2:02 Speaker 00 We're dedicated to bringing you inside coverage of the pharmacy nation's biggest events with on-the-street-style interviews, with keynote speakers, attendees, exhibitors, and recurring guests who make each year special. Stay tuned each week for a new episode of this special six-part series on the ASEMBIAS 2026 Summit, held this year in Las Vegas.
2:28 Speaker 02 Keith Kallmes is back on the Pharmacy Podcast Network here at the Asembia 2026. Keith, it's so good to see you.
2:35 Speaker 03 It's great to see you again, Todd.
2:36 Speaker 02 I was just talking to Harry Travis about you and he's like, my gosh, these guys are going everywhere and going to different conferences and speaking at panels. And I saw posts of you on LinkedIn at AMCP, actually. You were at AMCP and you actually did not only a presentation, but you kind of are helping to elevate standards in the usage of AI. I want you to tell our listeners about that.
2:59 Speaker 03 Absolutely. So, speaking of Harry Travis, Harry put on the AI pre-conference at AMCP. It was a great conference overall, particularly in the pre-con. I gave a talk on basically the rules for the road in AI in evidence synthesis. So, when you as a pharmacist are prescribing a drug, that's obviously gone through the formulary process. It's had a lot of experts look at the clinical epidemiological and economic evidence surrounding that drug and its class and its competitors. And they've made the determination on what drug works best in what indication and in what patient population. The rules for the road in that are changing. And there was actually the release of a new set of standards called
3:41 Speaker 03 the RAISE guidance. That stands for the Responsible Use of AI in Evidence Synthesis. It's a fast-moving field. They just came out with them at the end of last year. They've already gone through three iterations. So, they're really taking the whole concept of living guidance seriously. And I gave a talk. We are no longer speaking theoretically about the use of AI in evidence synthesis for pharmacy. We're talking about how it's actually being deployed. And I spoke at the AI pre-conference at AMCP in 2025. And it was like, how might one, how might one use AI when you're doing evidence synthesis for PNT? Now, it's, okay, we're doing it. What are the rules for the road? So, that's how quickly this has moved.
4:23 Speaker 02 Rules of the road and there was another term that you used first time I really heard this and now it's gaining traction in specialty pharmacy but throughout it's Horizon, what's it, how do you say?
4:36 Speaker 03 Horizon scanning.
4:37 Speaker 02 Horizon scanning, so tell us what that means.
4:40 Speaker 03 Absolutely, that's a really, it's another interesting use case for AI in pharmacy. It's almost at the opposite end of the spectrum from PNT. So I'll just note, for instance, and we were so happy to be a partner with them in this, but the students during the AMCP PNT competition use nested knowledge to make a formulary recommendation and that involved looking at every piece of evidence that involved going through all the literature, all the clinical efficacy data, all the economic findings to make a determination on whether or not a drug should be put on formulary. That has a human in the loop and AI is almost supplemental in that, right? It's like, it's there to make you more efficient. If you go look at the Horizon scanning application, this is something that I would say is fully automatable.
5:23 Speaker 03 It's something that you can genuinely outsource to an AI and an AIologist run this whole function for you. So let's say, you know, you're responsible for understanding what the way of the land is in a specific therapeutic area, you know, fast-moving therapeutic area, let's say, you know, metabolic dysfunction, obesity, diabetes, MASH, or oncology, right, like NSCLC, there's so many new therapies in the pipeline. It's an overwhelming amount of therapies and obviously you can't ignore them. Maybe one of these is gonna save some of your, you know, the people you're responsible for's life or save your plan a bunch of money or really transform the field. How do you stay on top of that?
6:07 Speaker 03 That's really what the concept of Horizon scanning is. That used to be a fully manual process. You would have to go and look at what drugs are in the pipeline, look at clinicaltrials.gov and understand, you know, what are the indicated patients, what's the inclusion exclusion criteria, what are the endpoints, you know, primary, secondary, exploratory. You have to go in and download individual records from clinicaltrials.gov, look at the indication, look at the sponsor, really understand what molecule is being used and see if it would be relevant to your formulary. Now you can have an AI do all that. You can have an AI go and pull all those records, build them into machine readable displays, and then have an AI extract who's the manufacturer, what stage is it at, what's the indicated population.
6:52 Speaker 03 And you'll also understand how you can then do a class review, right? You're almost pre-building a sort of comparative clinical efficacy analysis that you would do by understanding what that patient population is. Can you do an apples-to-apples comparison? So are the endpoints going to be the same? Is the molecule currently on the market? And yeah, I would say for Horizon scanning, we're there. That's something you as a pharmacist or a plant exec or whatever could set up tomorrow and just have a good read on what's coming in the next two, three, four years.
7:23 Speaker 02 How do people decide how to engage, when to engage the nested knowledge team? Like how are, because I automatically think of content developers. We absolutely, the entire infrastructure of evidence-based podcasting is setting on top of nested knowledge access to information and the right information and then future information that comes out, you're grabbing it, which I love. But for a specialty pharmacy or for an association or for, you know, a CE developer, like how is nested knowledge leveraged?
8:02 Speaker 03 That's a great question, and it really depends on the specific use case. So if you're in specialty pharmacy that you're talking about, like when you need to do that class review, when you need to understand what the landscape is, when you need to understand what the comparative efficacy is or what the EpiData is going to be, you know, how many patients am I going to have to give this to, right? In my specific population? That's an epidemiological review. That's an epidemiological review. We're going to go find the incidence and prevalence and we can map that on to, you know, maybe the racial or age demographics of your specific population that you're covering. So that's when you would use it for a pharmacist. For a society, that's almost a whole other end of the spectrum.
8:40 Speaker 02 Yeah.
8:41 Speaker 03 I've worked with some societies to develop guidelines. That's a core functionality of a lot of these societies. So the American Stroke Association did some guidelines in nested knowledge to work in some other societies to develop guidelines. And those are systematic reviews. Those are Understanding the clinical landscape, you know, what therapies and interventions are available to clinicians to deploy and really understanding what patient populations those should be used in, right? That's, that's all a guideline is. That's supported by a systematic review, often by a meta-analysis, actually. If it's in, if it's in a well-established therapeutic area and you want to understand, you know, what is going to give patients the most benefit, that is when a meta-analysis would come into, into play.
9:24 Speaker 03 So it, it really runs the gamut. Speaking of, you know, the whole evidence-based podcasting, look, finding references. This is something that you, this is something that you don't want to rely on LLMs for. I'm a huge fan of LLMs. I use them every week and, and they can really help with a lot of stuff, but you, you, you don't want to source your references from LLMs because they will give you fake studies. They will literally make up studies and feed them to you. So use them to do your first draft, use them like, I use them, again, every day I use them. Don't use them to find references. When you're finding evidence, do it in a traditional manner that is then AI-augmented. So definitely go to all the same traditional databases you would go to.
10:06 Speaker 03 You can have, you can have AI help you draft your query that's going to go to those databases, but you want to go to the databases specifically. You want to make sure that you're preserving the audit trail when you're finding that evidence, whether it's in podcasting or in formulating on the, or on the manufacturer's side, right? Like, we should all be operating from the same principles of reproducibility and provenance and replicability. You know, the, the biggest thing that I can say is you should be able to have someone else do the same research that you did. And if, even if they don't come to the same conclusion, they need to understand why you came to your conclusion, the data you're relying on, and vice versa. So that's, that's all I'll say for the whole, the whole evidence base is replicability.
10:49 Speaker 02 Yep. Keith Kallmes, nested knowledge. We are so excited that you're part of the network and giving us your support and your insights. Can't wait to have you back on This Week in Pharmacy.
11:00 Speaker 03 Thanks for having me, Todd. It's great to see you, as always.
11:06 Speaker 04 Hey, this is Hannah Baxter from the Dedham Group and you're listening to Pharmacy Podcast.
11:13 Speaker 05 Hannah Baxter, Andrew Rolfe, Dedham Group. Welcome to the Asembia post-show. How are you?
11:19 Speaker 04 Good, doing well, thank you. How are you?
11:21 Speaker 06 Happy to be here.
11:22 Speaker 05 All right, let's get right into this. What do you guys do in specialty pharmacy? Why do you invest the time to come to Asembia?
11:29 Speaker 04 Excellent. Well, good question to start us off with, so I can tell you a little bit about the Dedham Group. We're a life science consulting firm, so we focus on market access strategy and commercial strategy. So for us, being here and partnering with MMIT, a sister company under the Norcella branch, we're looking to help clients facilitate different relationships, support with any key questions that are coming up from industry insights that we're hearing on our side, from kind of different stakeholders across the ecosystem, and then as well as help kind of the information flow as well and provide strategic guidance. And then Andrew, can you talk about it?
12:05 Speaker 06 Yes, and I am at MMIT. We're a analytics and data company. I work on the market research and insights side of the organization, so what we do is put together exactly that, market research as well as insights to understand coverage, policies, claims, data, things like that, just to help manufacturers understand what's going on from a market access perspective.
12:25 Speaker 05 Andrew, when you look at the data, 30,000-foot view, are there any parts of rare disease that you're like, wow, there's an opportunity to improve the access, getting the patient started on the therapy, keeping the patient on the therapy? Are there any stories that you've seen? Because data for the right analysis and for the right consulting group can be a blinding light, where you're like, there it is, there's the issue. Share with our listeners some of your insights.
12:53 Speaker 06 Definitely. So, rare disease is particularly interesting. Rare disease is growing tremendously, tons at this point. There's tons of new drugs coming out in the rare disease space as technology gets better, or the science is just, the breakthrough is incredible at this point. So we have a lot of new technologies coming out that allow for rare diseases that have never even previously been identified to now be treatable. The problem is exactly What you just outlined from a market access perspective. Rare disease by definition is only a small amount of patients that have the disease, which means that consequently these new therapies that are very expensive to develop are very expensive. So from a market access perspective, what our clients really need to do is to make sure that the patients with these diseases can have access to their therapies at a reasonable
13:35 Speaker 06 price that they can afford and can stay on these brands. So manufacturers do this in tons of different ways. Patient Support Program comes to mind in particular. What they do with this is to help their patients get on brands and stay on brands, actually provide their own support. Just the financial support, logistics support. If you're trying to do a prior authorization and it gets denied, they can actually work with the patient as well as the HCP to make sure that you do get on the brand. So that's just one tactic of frankly dozens that manufacturers do to help patients get on there. But the rare disease, like I said before, it's growing probably about as fast as any area within pharmaceuticals today.
14:11 Speaker 02 Hannah, how is the manufacturer of these rare disease medications super expensive? Sometimes limited distribution. They're very choosy as to what specialty pharmacies they're working with. How have you and the Denim Group really identified barriers for the manufacturer and to bring information back to them and saying, here's an opportunity to improve?
14:41 Speaker 04 Yeah, it's a great question. I think with the world of distribution, models, channel ecosystems, enterprise entities, with the kind of quick evolution of what we've seen with partnerships, acquisitions, it's very important to look at the distribution channel. So when we think about a limited distribution network or something broader, we're assessing what do the vendors or what can they provide to the manufacturer to help them better understand the population? And then for the manufacturer, why does that particular vendor work well as a partnership? So it's evaluating both sides of the puzzle. Thinking about it from the distribution side, how can they help the manufacturer target the right populations, the right prescribers, sites of care? And then for the manufacturers, it's helping choose the right partner. So what type of support can they offer? What type of data?
15:25 Speaker 04 You meet to them. So it's a two-way system. So it's making sure when we're thinking about strategy, when we're thinking about who that limited distributor should be, maybe it's one, two, more than that. What's the appropriate side? What are the trade-offs to making that decision? Because it's a very critical point to get the product from, obviously, manufacturing down to the right prescriber sites.
15:44 Speaker 05 So Andrew, how has the biosimilar in cell and gene therapy explosion onto the market, especially within the last 18 months, two years? We're hearing that by 2030, there's going to be an additional 200 of these cell and gene therapies on the market. How has that impacted kind of the research that you're developing, as well as the attention that's being drawn towards these therapies?
16:10 Speaker 06 Definitely. Tons of attention to biosimilars in the last, exactly what you said, two to three years, maybe five years, but honestly, two to three has been a big explosion right now, and it is expected to increase in the foreseeable future. The two biosimilars that come to mind that really caused this explosion, I don't know if caused it or more of an effect, are Stellara and Humira. Massive brands that have tons of TAs, very high utilization, very successful brands, some of the most successful brands that have ever been developed. Loss of exclusivity happened recently, so biosimilars came to the market. For both of these brands, there are between five and 10 biosimilars that have been approved, maybe even more for Humira. So this is, again, it's been a big key driver of biosimilars, and there's been tons of attention to it from the payer landscape, as well as manufacturers, just
16:54 Speaker 06 to understand what it means, because we haven't seen biosimilars come to this much attention ever before. That means that payers are prioritizing different biosimilar first policies, requiring you to step through a biosimilar prior to getting on the originator brands. You have to go through a Humira biosimilar prior to the Humira itself at times. And more so than that, we've actually seen payers go through vertical integration in order to further prioritize these biosimilars. So partnering with biosimilar manufacturers to just do just that. They'll prefer that particular biosimilar first, and there's a partnership with the manufacturer that's beneficial for everybody. So the biosimilar trend, it's been around for, not a while, five years or so. By the last two or three years, massive explosion with these two brands.
17:37 Speaker 06 Zolaire recently came off patent, too, so there's a biosimilar for that. Plenty of other brands as well, too, Rituxan, things like that. And it's just going to increase, but they're looking at the Humira and Stellara blueprint for what it's going to mean for the future, is the key strategy we're seeing from manufacturers today.
17:54 Speaker 05 Hannah, how has women's health specifically, from a research perspective, become risen and is getting more attention than what it was, I remember, I don't remember much being talked about in fertility six to seven years ago. There's so much happening now specifically in women's health. Talk to us about your research and the opportunities that you're bringing to the manufacturers, but then also to the outlets.
18:22 Speaker 04 Yeah, it's a good question. We've definitely seen kind of surgeon therapies as it relates to women's health, and I think it's kind of across the board, whether we're thinking about fertility, ovarian cancer, different types of cancers as well. So I think it's great to see that much clinical development. The amount of products and clinical trials that's being evaluated is certainly helpful to kind of bring more to market. In terms of kind of what we want to think about from an access strategy point is the more products that come available, it does make it more of a competitive landscape. So how do we think about the right access channels, kind of what access looks like, what does good look like? We were talking a little bit about biosimilars, so obviously with that, management comes in. So as a therapy area or category gets more crowded, we want to make sure that the access restrictions are appropriate,
19:05 Speaker 04 that patients can get the right medically necessary products. So it's great to see this much innovation, and what we want to think about is how do we keep access open? How do we support manufacturers, target key strategies with whether we're talking about payers, providers, to make sure that those lines of access stay open, affordable for patients as well. So it's thinking about it from a few different angles, from an access strategy perspective, to make sure with all these products coming to market in new spaces, access remains open. And yes, it's good to have options, but what we want to make sure is those options don't translate to restrictions because there's a number of products available.
19:41 Speaker 05 All right. A Sembia 2026, this has been a rocket ship of activity. I want to thank MMIT and the Denim Group for being part of the pose show. Andrew, Hannah, thanks for being here.
19:54 Speaker 06 Thanks for having us. It's been a pleasure.
19:56 Speaker 04 Thank you so much.
20:00 Speaker 02 Here with Heather Baum from URAK. Heather, it's so good to see you again.
20:05 Speaker 01 Great to be here.
20:06 Speaker 02 Is this turning into a tradition for us? Because you were on our show last year.
20:10 Speaker 01 I was. I certainly hope so.
20:11 Speaker 02 It is. I love it.
20:12 Speaker 01 We'll see if I get invited back next year.
20:14 Speaker 02 Probably will. All right, URAK, extremely important organization helping to keep standards high in specialty pharmacy, all over pharmacy, but let's just focus on specialty. You had a new program that you kind of gave me a little bit of a hint about last year that's now become full power. Talk to us about that. What is, what's happening with, with URAK right now?
20:36 Speaker 01 Yeah, so, you know, our specialty pharmacy accreditation is clearly one of our most popular programs. And it's where my team, the pharmacy team, spends most of their time. Every three to five years or so, we revise the standards. And we do that by bringing together industry experts, what's important, what's changed, you know, how should we revise the standards? And we were in the process of that really all through 2025. In fact, we had a big session that we hosted at Asembia last year, taking advantage of everybody in specialty pharmacy being here. Got some feedback. One of the things we learned through that process was actually our standards pretty much were already hitting the mark. So we made a few changes with the revision and the current version of the program,
21:21 Speaker 01 which is version 6.0, is released. That's what organizations are being accredited under now. But it's not huge changes because the industry really, again, informed us that our standards were hitting the mark. A few things, we updated some of the telephone performance metrics, added a few things there. And then other things like dispensing accuracy, really shifting the focus of that to promoting safe dispensing and promoting a culture where reporting happens and can be addressed versus a punitive approach to when an error happens. So some, some kind of new...
22:00 Speaker 07 Shifting of concepts, but not wholesale new concepts. And we're getting really good feedback on the on the release of that, too.
22:07 Speaker 02 All right, so you also have dug deeper into rare disease specificity. I can't say that. See, that's why I'm not a pharmacist.
22:16 Speaker 07 Yes, specificity, maybe.
22:18 Speaker 02 Specialicity. And kind of tell our listeners about that, too, because that's very important.
22:22 Speaker 07 Sure, we've had a rare disease designation and now certification program for several years. It's one of the places where we are seeing more growth in the accreditation space. So specialty pharmacies that are dispensing orphan drugs to treat rare diseases that really require even more clinical care and even more patient support than the complex specialty therapies that we can, quote, "traditionally" talk about. We have a set of standards for that, too. And so you have the specialty pharmacy accreditation. On top of that, you can seek the rare disease certification. It's not for all specialty pharmacies. It's really only for those that are focusing on these very specific orphan medications.
23:06 Speaker 07 But we're continuing to see some growth in the number of specialty pharmacies that are heading in that direction and seeking that certification.
23:15 Speaker 02 All right, so the big topic here at Asembia, one of the top three, and definitely in our theme, is artificial intelligence specifically in specialty and what that means, how that differentiates from long-term care, compounding, or community pharmacy. Talk to us about the accreditation of what it is to use AI in specialty pharmacy.
23:38 Speaker 07 Yeah, absolutely. So in September of 2025, URAK launched the first national AI in healthcare accreditation. It was pretty natural for us. So, yes, we do a lot of work in the pharmacy space, but we're a national accreditor across healthcare. And a lot of the healthcare organizations that we already accredit were saying, hey, we're using AI, and we could use guidelines, standards as to how to.
24:06 Speaker 07 Implement, test, monitor, train our staff, all of that. So like we do for any program, we brought together industry experts and said, all right, what should this program look like? And it included users of AI health, AI systems in healthcare and also developers. And we actually pretty quickly realized the program should not only focus on users, but also developers. So it's a modular program and there are some foundational standards in it. But it has modules to say, hey, and so we have some organizations seeking accreditation right now and they develop and then they also use the AI systems that they, that they develop. So there are developers and users.
24:48 Speaker 07 And then we have some others that are, hey, we're using AI systems that someone else is developing for us. How do we do that? And then we have developers, hey, we just develop and we want to partner with organizations to use our AI systems. So it's.
25:03 Speaker 02 So it's fascinating.
25:04 Speaker 07 It's been a lot of fun.
25:05 Speaker 02 Think where it's all going and the standards are so important to keep, to keep things in check so that we can make improvements. If you don't have some, some way to check on how you're developing higher abilities to develop, deliver care through those standards, it's, it's hard to map it out, especially with the creativity of AI too.
25:27 Speaker 07 Exactly. And it's moving so fast, right? But that's why accreditation works. So, you know, really as a country, we're struggling with regulations around AI. There have been so much, there has been so much legislation on the federal level, on the state level. And I mean, think about that, different states having different regulations. How could anybody, particularly a national healthcare provider, you know, maintain compliance with all of that? So accreditation just works because we can offer a national healthcare accreditation that can apply to really any kind of AI system. Because we're not saying, hey, you have to do X, Y, and Z. It's saying it's a structure, right? Hey, you need to make sure that you are, you know, testing before you implement, you're
26:12 Speaker 07 training your staff so that they know what the system's intended.
26:16 Speaker 01 Use is and what your expected outcome should be. And if you don't get that outcome, what do you do about it? Who are you reporting back to? What does the monitoring look like? How are you disclosing to other stakeholders? Just all of that infrastructure, but that infrastructure can fit to really any kind of AI system that is being used in the healthcare setting. It doesn't have to be so specific. And we have the ability to circle back with our advisory group and make potential updates to the standards in a way that regulations don't really have that flexibility. So accreditation just works in this in this space.
26:54 Speaker 02 Heather Baum, thank you so much for participating in the Access to Pharmacy Asembia Show. We really appreciate you being here again. So thank you.
27:03 Speaker 01 Yeah, it's been great being here. Thanks.
27:07 Speaker 05 Hey there. Jeremy Richardson, CCO with Gift Health. You're listening to the Pharmacy Podcast.
27:14 Speaker 02 Hey, technology, my goodness, it's really transforming. Been in this industry for over 20 years. It's moving through benefit coordination and patient engagement communication, direct to patient models. It's almost, in some ways, it's like the Wild West, but it's a controlled madness of things that are happening. We need organizations that really center on patient first, medication, management and treatment. I'm so glad to meet up with you, Jeremy, with Gift Health. How you doing here at Asembia?
27:47 Speaker 05 Doing well. It's a crazy busy time. It's really interesting to be here when the industry is just evolving so quickly, but we're having a great time. We're really excited to be leading the charge.
27:59 Speaker 02 Just in case our listeners who didn't get to attend Asembia, didn't get to come to your booth, give us a summary. What is Gift Health?
28:08 Speaker 07 So Gift Health, we were established in 2020 and we are a digital pharmacy. And we are really focused on end-to-end solution where we eliminate the handoffs, where we can take care of patients end-to-end and really presenting that option to the industry and just sharing what we have and taking that from a perspective of, you know, developing this world where there were so many handoffs and there were so many issues that patients had and now we can really help patients, we can help providers, we can help manufacturers to really consolidate that journey and really have a full service partner.
28:50 Speaker 02 We're in an age of, and there's something good about this and then there's something bad about this. We could actually talk for hours, Jeremy, on the philosophy of speed to information, access to information. Sometimes the consumer getting access to too much information will confuse things. Whereas Gift Health is really putting these guardrails around an opportunity for patients to come back to Gift Health, ask lots of good questions and not have to go through silos and not have to go through a bunch of data they don't understand. So talk to us about that ecosystem that you guys have created.
29:29 Speaker 07 So what's interesting is I feel like the industry for a long time and in a lot of great ways has really focused on the script journey, the prescription journey. But now we are really hyper-focused on the patient journey, right? What is that experience like? Like, how do you engage the patient? How do you do it immediately? How do you do it in a fashion where the patient doesn't, they don't lose the information, they don't lose the interest from the time that they're prescribed the medication, right? Where they understand what this journey is going to look like, what's this journey is going to feel like. And so Gift Health, what we do is we engage immediately and we make sure that the patient understands what to expect, right? So you set the right expectations and then the patient knows, the provider knows, the manufacturer partner knows, they know what to expect, right? And when you do that, you can really set the standard and you can understand what
30:14 Speaker 07 this is going to look like, what this is going to feel like and be a really good partner throughout the process and throughout the journey.
30:19 Speaker 02 About five, maybe up to seven years ago, the advent of AI really came into specialty pharmacy. Whereas today, it's already been proven. There's things that are working very well. There's even standards being created to continue to build out where AI is going to take specialty pharmacy. Gift Health has really leveraged the fusion of AI and the human experience and humans being involved. We're not just leaving it just to AI. Talk to us about the combination of AI and then the human touch.
30:57 Speaker 07 So we think it's incredibly important to keep the human touch. But we also think it's really important to lead with technology, meet the patients where they are. And in doing so, what we've found is there is an overwhelming number of patients that want to engage virtually. They want to engage in different ways. They want to be found where they are. They want to be found very quickly. And in doing that, what it does is it gives the patients optionality. And we see the patients engage. They like the journey when you give them that option and you can connect with them when they want, where they want. And that's something that's really different to the industry. And so finding that cadence, finding that opportunity to meet the patient where they are has been really, it's been a really good opportunity for us
31:42 Speaker 07 to kind of change where the industry meets the patient.
31:45 Speaker 02 I've talked with one of your colleagues and one of the statements they made that I wanted to ask you more about was removing friction in the ecosystem and making e-commerce super simple and simplicity for the patient to check out and for automating data reporting and even the predictive analytics that are available to us based on how much data is out there. Talk to us about how Gift Health has really leveraged.
32:15 Speaker 02 AI and technology in general to remove friction within the ecosystem.
32:21 Speaker 07 Yeah, it's it's an interesting opportunity that you that you have with the patient, you know, from the front end. And so the way the way that we've leveraged that is you find you find the patient very early in the journey, right? And in finding that patient and understanding how they want to engage and leveraging that, you know, it gives you the unique ability to be be a little bit different, set a little bit of a different industry standard. And so we utilize the technology to bring the script in very quickly, right, to engage the patient before they have the opportunity to, I don't want to say lose interest, but I want to say before they have the opportunity to misunderstand the journey, right, or or
33:03 Speaker 07 look at alternative options and feel like they're disconnected from their provider. And so connecting with them early and taking the script quickly is really allowed us to change, you know, the whole dynamic and the whole timeline of what the patients expect. And I think that's the biggest that's the biggest proponent that we have is is changing the expectations that the patients have, because I think that in a lot of cases, the patients feel like the journey is working against them. And now I think that they're feeling like Gift Health and others are advocates for them.
33:33 Speaker 02 Jeremy, I want to thank you for spending time with us at the press booth here, 18:05 at Assembia. I can't wait to follow up with you guys. I have more questions, want to dig into how you're assisting specialty pharmacy, specifically in the expansion of what Gift Health is presenting to our patients. And thank you so much for being here.
33:51 Speaker 07 Absolutely. Really appreciate the time. Thank you again.
34:00 Speaker 00 The Pharmacy Podcast Network would like to thank our sponsor for supporting us at the 2026 Assembia Summit. Clearway Health is transforming specialty pharmacy for hospitals, health systems, and the patients they serve. Clearway Health is more than a specialty pharmacy partner. They're an extension of the care team, working directly with hospitals and healthcare systems across the country. Clearway helps plan, design, build, and optimize. specialized specialty pharmacy programs that improve access, reduce barriers, and deliver better outcomes for patients with complex medical conditions. Through their embedded care model, Clearway Health places pharmacists and patient liaisons directly into clinical workflows, supporting providers with prior authorizations, financial
34:44 Speaker 00 assistance coordination, and patient education, so care teams can focus on what matters most: the patient. Powered by advancing technology and real-time data insights, Clearway Health streamlines the entire medication journey, from prescription to adherence, ensuring patients receive the right medications at the right time. Born out of Boston Medical Center Health System, Clearway Health brings real-world experience and proven results, helping health systems unlock new revenue streams while expanding access to life-changing specialty medications. As we head into Asembia 2026, Clearway Health is leading the way in refining specialty pharmacy, where clinical excellence meets operational innovation. Learn more at ClearwayHealth.com.
35:33 Speaker 02 Joe DePinto, Head of Cell and Gene Advanced Therapies at McKesson, back on the Pharmacy Podcast. It's so good to see you, Joe.
35:41 Speaker 05 Great to see you, Todd. Thanks for having me.
35:42 Speaker 02 We're here at the Super Bowl of specialty pharmacy. So excited to be here. This is probably one of my favorite conferences to gather together. What do you like about Asembia? What do you like about coming here?
35:52 Speaker 05 It's a never-miss conference for me. I think I've been coming for 20 years or so, and it's always great to talk with like-minded folks around some of the challenges and opportunities in patient care. And specialty pharmacy continues to play such a really important role in patient care, especially in my area. So it's great. It's great to see old friends. It's great to listen to new topics. It's great to participate. And every year, I think it can't get bigger and better, and it seems to.
36:21 Speaker 02 Well, you've been on This Week in Pharmacy several times giving us updates on cell and gene and where we are. You're moderating a panel at Asembia this week on breaking through reimbursement complexities for cell and gene therapies. What's that conversation about? What are you hoping to obtain with that conference?
36:40 Speaker 05 You know, I'm really excited to do this panel. We've got a great bunch of presenters and subject matter experts. Everything from a physician who leads the Sarah Cannon Group as well as HCA around cell, gene, and advanced therapies. We have a director of pharmacy for a big health plan as well as a group of treatment centers, Geisinger. And we also have an innovative health economist CEO of a risk, a company that just came out of stealth mode that's looking at unique reimbursement and risk models. The space is complex and the reimbursement challenges have been well documented and we need to have different thinking
37:22 Speaker 05 to be able to tackle that for patients to have better access. My goal in this panel is to get that thinking moving in the direction of solutions rather than laying out just the problem. So I'm excited about it. It should be a fun panel. I know I'm going to have a really interactive panel because these panelists are just super knowledgeable and super personable.
37:42 Speaker 02 I love that. And the people that come here are passionate about what they do. And we've been soaking in this for so long. We've seen changes all along. I've seen changes in technology. I've seen changes in drug development. What do you think has been the biggest challenges in the cell and gene space over the last 12 months?
38:03 Speaker 05 So, cell and gene therapy continues to evolve as a marketplace. The science is well documented and is unbelievably strong. Where we've had a challenge is moving from the science to commercial patient access. I think we've made some progress with the community expansion of moving cell and gene therapy treatment out of the teaching institutions to more of the community hospitals and eventually the community clinics. So progress has been But look, it's still not to a point where the patients have access that we'd all like to see, where they don't have to travel distances to go to see a treatment center and that there's untethered access to these products, which is really important because the science
38:47 Speaker 05 is fantastic. So how do we transition the clinical science to commercial patient access is going to continue to be a focus. We're making progress. I don't think fast enough that any of us like it.
38:58 Speaker 02 So I know in covering every aspect of our pharmacy industry, it's the specialty sector that always has the issues around reimbursement and getting reimbursed. What makes cell and gene therapy reimbursement particularly challenging?
39:14 Speaker 05 So there's a, the challenges in cell and gene, the barriers are multifactorial, right? Reimbursement's absolutely one. Plus, in some of these therapies, they're all a bit different. Cell therapies are different than gene therapies, different price points, different dosing, different approaches to patient care. We're starting to see more and more of these approaches move outpatient, right? Which is great. The challenges we see on the reimbursement side are that typically our healthcare system's not set up for reimbursement where there's a cost density component, where you pay upfront and then you see the benefit over an extended period of time. That's counter to our healthcare system and reimbursement in our healthcare system. So I think we're dealing with some of that.
39:59 Speaker 05 I think we're dealing with making sure the appropriate patients get the appropriate product. And I think as an ecosystem, we're really fundamentally looking at how do we best transition from all that clinical promise to commercial access?
40:12 Speaker 02 Yeah, exactly. So when you think of the field itself, I get excited because I see pharmacists becoming specialists in cell and gene therapy and understanding it in its component and its vertical. But where do you, where do you see the field headed? What's the role of the pharmacist?
40:30 Speaker 05 I think the farm, I've told you this in the past when I've visited with you, I think the pharmacist plays a critical role in the treatment team of cell and gene therapy patients. So the beauty of cell and gene therapy, that complexity is a clinical complexity, it's an operational complexity, and it's a financial complexity. Who best to sort of connect all those? Dots and coordinate, but the pharmacist who has that operational, that clinical and that financial acumen to be able to help patients navigate that complexity, to help health systems deliver more efficiently the products and to help biopharma make sure that as they approach the commercialization of the products, it's being done in the right
41:14 Speaker 05 way. So I think cell and gene therapy is a high user of pharmacy on a regular basis.
41:21 Speaker 02 Joe, we always appreciate your insights. Appreciate you being here at the Asembia 2026 coverage and hope to have you back on this week in pharmacy.
41:30 Speaker 05 My pleasure, Todd. Always good to see you. Thanks for having me.
41:33 Speaker 02 All right. I want you to say, hey, this is Joe DePinto and then, you know, whatever title and you're listening to the pharmacy podcast.
41:41 Speaker 05 Okay.
41:41 Speaker 02 Ready in three, two, one.
41:43 Speaker 05 Hey, this is Joe DePinto, a head of cell, gene and advanced therapies at McKesson, and you're listening to the Pharmacy Podcast Network.
41:56 Speaker 02 Look who showed up at the Asembia 2026 event, Johnny Kello with MatchRx. How are you?
42:02 Speaker 05 Hey, Todd. Thanks for having me, buddy. I just was walking by and I knew you were going to be here. So yeah, it's good to see you as always.
42:09 Speaker 02 It's nice to see you too. I know that you, I know that MatchRx, the power is in the independent pharmacy space, community pharmacy space, long-term care. However, there are the sprinkling of specialty pharmacies that are playing in areas where MatchRx could kind of plug into. Talk to us about your experience here and just being in this environment.
42:33 Speaker 05 Yeah, so this has been exploratory for us. You know, it's interesting. It's a little bit of a different animal than what we normally deal with on the independent side. So we're just starting to get our feet wet with specialty, trying to understand, is it a fit for us?
42:53 Speaker 06 One of the things that we've been really conscious of over the years is not chasing every shiny nickel, staying focused on who we are, what we do really well, which is helping the independent space and bringing that at every level. And the reason we expanded with the feedback from our members into the wholesale space. So you'll see now we've got 15 secondary wholesalers, Anda just joined us, which we're really proud of because considering the newbie that we are on that side of the equation now over a year, we're only one of I think
43:31 Speaker 06 two or three marketplaces that Anda chose to be partnered with. So again, to the specialty piece, we are again, just kind of uncovering and understanding. And then if that's an opportunity where we can help in that space, we'll go ahead and do it in a diligent manner. But again, today is just primarily exploratory, although we've run into a lot of other partners here, which is great. ASEMBIAS is such a big conference. You don't have to say, hey, you're here just for one thing, because there's so many ancillary vendors, partners that are here.
44:10 Speaker 02 That's why Armada Health, which was the company before becoming ASEMBIAS, that's why they changed their name to ASEMBIAS, because the term ASEMBIAS is to assemble together, to do more together and be more powerful together for the patient than what you are by yourself. So that's your whole attitude at MatchRex is bringing people together. As a matter of fact, for our podcast listeners, listening to the ASEMBIAS post show, MatchRex has a special three-part series out on our network for This Week in Pharmacy, where you've brought together several experts on DSCSA and the politics of where we are in pharmacy. So we really appreciate that support.
44:49 Speaker 06 Yeah, no, I appreciate you guys getting the word out because again, it continues to be an education to independents. Everybody's still understanding, what is an EPSUS file? What is DSCSA? Am I obligated to follow through on each piece of that? And the short answer is yes. There's carve-outs and But come November 27th of this year, you really have to understand, you know, what your requirements are as an independent, how you bring product into your store, how you track that product. And that's one of the reasons we partnered up with LSpedia is we've become their exclusive marketplace reseller because we believe in what they're
45:33 Speaker 06 doing. We did it at a price that's severely discounted to the retail price because we want independents to, you know, make sure that they get on board at the best opportunity, the most reasonable opportunity and understand what those needs are. I think those kinds of things are what we're doing today to educate people before November 27th. And that's just one. You know, we had Alisa Bernstein. Alisa, you know, I would say is the foremost authority on DSCSA. She led the FDA in the launch of the DSCSA before she left the FDA. We had
46:15 Speaker 06 Said Dino, who really understands GCR. Again, another key component to buying when you're buying from your pharmacy, understanding, you know, what's contract and what you should be looking at outside of contract because you're not maximizing savings by buying from your primary. You're actually depleting. But there's a balance, right? We're not suggesting you do all your work with your primary, but we're also suggesting that you be smart about where you can buy outside of contract because, you know, if it's 3,000, if it's 5,000, if it's $10,000 a month, it's your money. Take the time, train your team, help, you know,
46:57 Speaker 06 have them call us. We'll help train the team. These are things that, again, it's just those little things that people have to understand to create processes for. Yep. You know, every business is a people, it's processes. Those are the two key components. And when you have the right person and you've got good key, a good process, I think you can make a lot of those little things that people consider bothersome work for your benefit. It's not a cost and it's an investment. And so I think, you know, people get caught up with day to day, but, you know, we operate under the EOS operating system and it tells you all The time if you're working in your business, you're not working on your business. So as independent pharmacies, sometimes you have to pause, pull yourself off the, you know,
47:42 Speaker 06 the counter and filling scripts and you have to work on your business, not in your business. When you do that for that 10, 20% of your week, you're going to see progress on the bottom line. If you're only working in your business, what you're doing is you're sitting on a hamster wheel and spinning and you're not really pulling yourself off and looking from 5,000 feet to really understand and develop processes. And by the way, I don't care if you're a newbie into the business, or if you've been a pharmacist for 35 plus years, it's never too late to learn how to work on your business. So if I'm going to leave you with anything, it's to have people
48:27 Speaker 06 recognize that they should be working on their business as much as they're working in their business.
48:32 Speaker 02 Johnny Kello, MatchRx. Learn more at matchrx.com. Johnny, thanks for stopping by.
48:38 Speaker 06 Thank you, Todd.
48:42 Speaker 05 Hey there. This is Sean Griffin with UREC and you're listening to the Pharmacy Podcast.
48:51 Speaker 02 Sean, thanks for joining us at the Asembia 2026 post-show coverage. This is the access to pharmacy. I call it the Super Bowl of specialty pharmacy. And your colleague was on with us and she's just brilliant and I love talking to her. I've talked to her several years in a row, but talk to us about UREC's mission and some of the things that we were talking about before you we started recording was having standards for providers to rely on. So they don't have to have any, there's no guessing of what those standards are.
49:24 Speaker 05 Yeah. So UREC's been around for 35 years. So we actually started back in utilization review. That's where the UR in UREC comes from is utilization review. And so we, we get together experts, we build programs, and then we act like an independent quality auditor to come in and actually check to make sure that things behind the scenes match what people are saying. And so the AI program was developed because we were watching AI come into so many parts of healthcare. And the thing that we were most concerned about wasn't the technical, there's, there's technical standards and those sort of things. It's more about the governance and the oversight and, and building the trust. One of the analogies that I often use is if you think about an AI tool, if it was A person, you'd be wanting to credential them. You'd be wanting to know where they went to school. You'd be wanting to know, you know, how long do I have to keep an eye on you since you're
50:08 Speaker 05 a new person or organization before I trust you? Are you doing something incredibly high risk or is it something low risk? And, and building an oversight plan based upon the risk that's posed to patients. And I think that right now, this is such a gray area. And in AI, it's very tough to tell the good guys from the bad guys. I always say, you can't tell if it's coming from Google or six guys in a garage. And, and so, all of these things are being sold. There's billions of dollars being thrown at AI right now. And healthcare is a very fertile field for organizations to come in and try and make money off of their tools.
50:41 Speaker 02 All right, so, Eurak has a mission ahead of you to really define, how far are we from having a standard, just in guest estimations?
50:52 Speaker 05 Well, we actually have a program.
50:53 Speaker 02 Oh, okay.
50:54 Speaker 05 Our, our program came out in September last year.
50:56 Speaker 02 Okay.
50:56 Speaker 05 Uh, it's the first AI in healthcare accreditation. We had an advisory group who started at the beginning of last year. And when we got the advisory group together, we were planning on building just one program. It was actually going to be for users of AI in healthcare. And when we got the group together and it was, we had 70 applicants for 29 spots in our advisory committee, everything from academic medical centers to pharma companies, to pharmacies, to practicing physicians. They said, yes, we need some standards around the users, but we also need one for the developers. So, our program actually has one for the developers and one for the users. The developer one is all about, you know, data integrity. It's about contracting, it's about transparency, all the things that you would think about when it comes to developers doing things in the right way.
51:37 Speaker 05 The user one is about contracting, where's the liability sit when you sign a contract for an AI tool? Is it being used for what it's designed for? Also, the business reliability of the organization that built it. I mean, it'd be terrible to buy some AI tool and three months later, they go out of business and you're left hanging high and dry. And so, it's, it's all about those sort of reliability of the organizations, reliability of the rollout. And then also, AI introduces some risks that we're not used to in, in technology tools, drift, hallucinations. Uh, you know, AI changes depending upon how it's implemented from, from Monday to Monday afternoon. It used to be when I was a CMIO, if I put in an order set in January, it was the same order set in March. And now, it's changing by the afternoon with some of these AI tools.
52:21 Speaker 06 And also, there's a black box component to a lot of AI tools. If you ask the AI experts, they say, "We're not exactly sure how it works." Well, we've never let something come into medicine without an evidence base and without an understanding. You know, when I was practicing as a physician, I said, "Show me the studies where this is better than what I was doing before." Now, it's, "Look at this really cool thing that happens in this black box, and I can't explain it to you, but I'd like you to use that in the care of your patients today, please."
52:47 Speaker 02 All right. So, calling out to specialty pharmacies and specialty pharmacy organizations, is there anything that's novel, is there anything coming up that they should be paying attention to that URAK is putting a lot of emphasis or investment in?
53:05 Speaker 06 Well, I think when you look at specialty pharmacy, I mean, there's an arms race going on right now around prior authorizations, agentic AI, all of these sort of things, and it's moving incredibly fast, and it's moving faster than regulations are giving you safe lanes. And we're not here to stifle innovation. We actually say, you know, if you're driving a race car, you still wear a seatbelt to hold you in place. AI has no seatbelts right now. So, we say that our program is about guardrails, not roadblocks. And so, we want it to be done right. We think it holds tremendous promise, but there's also known risks and there's unknown risks. And so, you know, take a look at our standards that are out at URAK.org on our website. You can see our standards at a glance that talk about everything that we look at.
53:47 Speaker 06 For example, when we talk about oversight of an AI tool, we talk about technical oversight, clinical oversight, and ethical oversight. And I think that, you know, we all see the horror stories that pop up on the news about somebody falling in love with their chatbot, or somebody using, you know, some tool to plan their school shooting or something like that. And this is just a dangerous area right now, and we think in this Wild West that URAK could be a trusted sheriff. We say that we can't have the wolves guarding the chickens right now. And so, having somebody who sits outside, who's looked at all the best practices, the 45 or whatever best practices that are out there, and brings the trust that you have for URAK and the role that we have played into specialty pharmacy and to all the other areas of healthcare is incredibly important.
54:29 Speaker 06 A lot of the concern right now also is, as people try and control this space, there's concern about a patchwork, whether that patchwork be different states have different rules, different emphasis that they follow. We're concerned about a patchwork where there's going to be one set of rules for doctors, one set of rules for hospitals, one set of-
54:44 Speaker 05 ...for pharmacies and then you don't even know what you're dealing with.
54:47 Speaker 02 Yeah.
54:48 Speaker 05 And so we just think that having an accreditation for AI in healthcare that applies to anybody in healthcare from an organization that was best in business for accreditation the past two years and has been trusted, we think that it's filling a gap.
55:01 Speaker 02 Sean Griffin, I want to thank you. I want to thank Eurak for spending time with us at Asembia 2026. I can't wait to have you guys back. I want to learn more and I have I have my own standardization that we're trying to work with, talk to to your team a little bit about, but I'll definitely follow up with you on it.
55:21 Speaker 05 And we should have some people get through the accreditation by June and we'll be doing a whole wave of publicity when that comes out.
55:27 Speaker 02 I'll be there. Thank you.
55:28 Speaker 05 Thanks.
Previous U.S. Supreme Court and Generic Drugs | TWIRx Next The Truth About Unexplained Infertility with Nick Dorsey | The Holistic Pharmacy Podcast Page updated November 14, 2026 · transcript and summary are machine-generated